Home Equities European Growth Stocks Insiders Are Backing
Equities

European Growth Stocks Insiders Are Backing

Share


As European markets navigate a period of volatility, with the pan-European STOXX Europe 600 Index ending a recent week nearly unchanged and major indices like Germany’s DAX and Italy’s FTSE MIB showing declines, investors are closely examining corporate earnings and geopolitical developments. In this environment, growth companies with high insider ownership can be particularly appealing as they often signal confidence from those closest to the business in its long-term potential.

Top 10 Growth Companies With High Insider Ownership In Europe

Name Insider Ownership Earnings Growth
MilDef Group (OM:MILDEF) 10.3% 30.9%
Kuros Biosciences (SWX:KURN) 26.1% 58.4%
KebNi (OM:KEBNI B) 11.8% 90.9%
Hacksaw (OM:HACK) 13.2% 23.7%
Dellia Group (OB:DELIA) 29.9% 47.9%
CTT Systems (OM:CTT) 17.4% 55.3%
Clavister Holding AB (publ.) (OM:CLAV) 20.7% 73.9%
CD Projekt (WSE:CDR) 35.2% 29.7%
Bonesupport Holding (OM:BONEX) 10.6% 32.6%
Bergen Carbon Solutions (OB:BCS) 11.9% 50.2%

Click here to see the full list of 216 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Let’s dive into some prime choices out of the screener.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Atea ASA offers IT infrastructure and related solutions to businesses and public sector organizations across the Nordic countries and Baltic regions, with a market cap of NOK18.23 billion.

Operations: The company’s revenue segments are distributed as follows: Norway generates NOK10.16 billion, Sweden contributes NOK15.52 billion, Denmark accounts for NOK8.65 billion, Finland provides NOK3.58 billion, the Baltics add NOK2.15 billion, and Group Shared Services contribute NOK13.69 billion.

Insider Ownership: 28.6%

Atea ASA demonstrates strong growth potential with high insider ownership, as evidenced by a significant 54.2% earnings increase over the past year and forecasted revenue growth of 6.6% annually, outpacing the Norwegian market. Recent Q2 earnings showed sales rising to NOK 10.42 billion from NOK 9.14 billion year-on-year, while net income increased to NOK 218 million from NOK 157 million. Despite this, its dividend yield of 4.58% isn’t well-covered by free cash flows, indicating potential financial constraints.

OB:ATEA Earnings and Revenue Growth as at Jul 2026
OB:ATEA Earnings and Revenue Growth as at Jul 2026

Simply Wall St Growth Rating: ★★★★★☆

Overview: DNO ASA is involved in the exploration, development, and production of oil and gas assets across the Middle East, the North Sea, and West Africa, with a market cap of NOK17.60 billion.

Operations: The company’s revenue is primarily derived from its oil and gas activities, totaling $1.91 billion.

Insider Ownership: 13.1%

DNO ASA, with substantial insider ownership, is poised for growth as it forecasts revenue expansion of 6.8% annually, surpassing the Norwegian market. Analysts anticipate a stock price increase of 23.3%, and earnings are projected to grow by 45.69% per year as the company transitions to profitability in three years. Despite high debt levels and an unsustainable dividend yield of 8.05%, DNO’s recent Carmen discovery enhances its asset base with significant resource potential in the North Sea.

OB:DNO Ownership Breakdown as at Jul 2026
OB:DNO Ownership Breakdown as at Jul 2026

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (publ) is a Swedish company that develops biological drugs for central nervous system disorders, with a market cap of SEK27.22 billion.

Operations: The company’s revenue primarily comes from its biotechnology segment, which generated SEK1.15 billion.

Insider Ownership: 32.2%

BioArctic’s growth potential is underpinned by high forecasted earnings growth of 53.3% annually, significantly outpacing the Swedish market. The recent FDA approval for its Alzheimer’s treatment, Leqembi Iqlik, introduces a convenient subcutaneous administration option that may enhance patient access and flexibility. Despite a decrease in profit margins from last year, BioArctic’s strategic alliances and innovative drug development partnerships position it well for future expansion in neurodegenerative treatments.

OM:BIOA B Earnings and Revenue Growth as at Jul 2026
OM:BIOA B Earnings and Revenue Growth as at Jul 2026

Summing It All Up

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders.
It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities.
All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We’ve created the ultimate portfolio companion for stock investors, and it’s free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com



Source link

Share

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

‘Why Nigeria’s industrial future depends on private capital’

With government losing its spending power to falling revenue and an increase...

Top European Dividend Stocks For July 2026

As the pan-European STOXX Europe 600 Index remains largely unchanged amid global...

Is W. R. Berkley (WRB) Expensive On Strong Q2 Earnings And Record Investment Income?

W. R. Berkley (WRB) stock is in focus after the insurer reported...

Blackstone’s AI Bet Fuels Blowout Growth While Rivals Grapple With “Zombie Funds”

Blackstone knows what the characters on The Walking Dead took a couple...